Ensuring a Consistent Supply of Anthrax Vaccine

DSpace/Manakin Repository

Ensuring a Consistent Supply of Anthrax Vaccine

Show simple item record

dc.contributor.advisor Hutt, Peter Barton en_US
dc.contributor.author Gelfand, Rebecca A. en_US
dc.date.accessioned 2012-06-07T20:11:22Z
dc.date.issued 2002 en_US
dc.identifier.citation Ensuring a Consistent Supply of Anthrax Vaccine (2002 Third Year Paper) en
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:8852116
dc.description.abstract During the recent anthrax attacks, the country's supply of anthrax vaccine was dangerously low. The reasons for this were (1) the failure of the FDA, the Defense Department, and its contractor, BioPort Corporation, to plan adequately to ensure the production of a consistent supply of the vaccine in accordance with the FDA regulatory process; and (2) the reliance of the Defense Department on a single private supplier of the vaccine with serious financial problems. Careful planning should be employed to prevent such a situation with other biological products which may be needed to save lives during bioterrorist attacks. en
dc.language.iso en_US en
dash.license LAA en_US
dc.subject Food and Drug Law en
dc.subject vaccine, en
dc.subject anthrax, en
dc.subject FDA, en
dc.subject defense, en
dc.subject biologics en
dc.title Ensuring a Consistent Supply of Anthrax Vaccine en
dc.type Paper (for course/seminar/workshop) en_US
dc.date.available 2012-06-07T20:11:22Z

Files in this item

Files Size Format View
FDA_paper.rtf 128.9Kb RTF file View/Open
FDA_paper.pdf 223.5Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters